This study investigated the ability of the immunosuppressant FK506 to rever
se nerve allograft rejection in progress. Eighty-four Buffalo rats received
posterior tibial nerve grafts from either Lewis or Buffalo donor animals.
Allografts were left untreated for either 7, 10, or 14 days before receivin
g daily subcutaneous FK506 injections (2 mg/kg). Time-matched control anima
ls received either an isograft, an allograft with continuous FK506, or an a
llograft with no postoperative FK506 therapy. All animals underwent weekly
evaluation of nerve function by walking track analysis. Experimental group
animals were sacrificed either immediately prior to initiation of FK506 the
rapy (days 7, 10, or 14), after 2 weeks of immunosuppressive treatment, or
8 weeks postsurgery. Histomorphometric analysis, consisting of measurements
of total number of nerve fibers, neural density, and percent of neural deb
ris, demonstrated a statistically significant increase in regeneration in t
he isograft group relative to the untreated allograft group within 28 days
of transplantation. Grafts harvested from animals receiving 2 weeks of FK50
6 after 7 or 10 days of rejection were histomorphometrically similar to tim
e-matched isografts. By contrast, grafts from animals receiving 2 weeks of
FK506 following 14 days without therapy resembled untreated allografts and
demonstrated significant histomorphometric differences from isografts at th
e corresponding time point. Analysis of walking track data confirmed that r
elative to untreated allografts, functional recovery was hastened in animal
s receiving an isograft, or allograft treated with FK506. This study demons
trated that when started within 10 days of graft placement, FK506 could rev
erse nerve allograft rejection in rats evaluated following 2 weeks of treat
ment.